SOLIGENIX, INC.
Late-stage biopharma developing treatments for rare diseases and public health threats.
SNGX | US
Overview
Corporate Details
- ISIN(s):
- US8342233074
- LEI:
- Country:
- United States of America
- Address:
- 29 EMMONS DRIVE, 8540 PRINCETON
- Website:
- https://www.soligenix.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases with unmet medical needs. The company operates through two distinct business segments: Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics pipeline is dedicated to developing treatments for orphan diseases, including its product candidate HyBryte™ for cutaneous T-cell lymphoma. The Public Health Solutions segment focuses on creating vaccines and therapeutics for infectious diseases and biodefense threats, such as ricin poisoning, with programs funded primarily through government grants and contracts.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all SOLIGENIX, INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for SOLIGENIX, INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for SOLIGENIX, INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
